Сравнение

Buserelin vs. Icatibant

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

57982-77-1

138614-30-9

Молекулярная масса

1239.42 g/mol

1304.52 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Buserelin	Icatibant
Германия	Рецептурный	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Buserelin and Icatibant?: Buserelin is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Icatibant?: The highest available evidence level is "РКИ на людях" for Buserelin and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Icatibant in Germany and the United States?: Германия: Buserelin — Рецептурный, Icatibant — Рецептурный. США: Buserelin — Не одобрено, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Icatibant

Германия

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Buserelin and Icatibant?

Buserelin is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Icatibant?

The highest available evidence level is "РКИ на людях" for Buserelin and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Icatibant in Germany and the United States?

Германия: Buserelin — Рецептурный, Icatibant — Рецептурный. США: Buserelin — Не одобрено, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.